Injurytalk.com - Brought to you by Parker Waichman Alonso Mark, LLP

Forum

On September 15, 1997 the FDA asked American Home Products (now Wyeth), the manufacturer or fenfluramine (Pondimin) and dexfenfluramine (Redux) to voluntarily remove these drugs from the market. These anti-obesity drugs were prescribed by themselves or in combination with phentermine for weight loss. "Fen-Phen" refers to the use in combination of fenfluramine and phentermine.

The FDA decision to remove the drugs came after researchers at the Mayo Clinic and Mayo Foundation reported 24 cases of rare valvular disease know as Primary Pulmonary Hypertension or PPH in women who took the "fen-phen" combination therapy. Subsequently, FDA received 66 additional reports of heart valve disease associated mainly with "fen-phen." There were also reports of cases seen in patients taking only fenfluramine or dexfenfluramine.

Primary Pulmonary Hypertension can take years to develop. If you or a loved on took Fen Phen and was diagnosed with PPH you may have valuable legal rights, please complete the case inquiry form of the right side of this page for a free consultation.